| Literature DB >> 22915785 |
Reem Yunis1, Huguette Albrecht, Karen M Kalanetra, Shiquan Wu, David M Rocke.
Abstract
This study aimed at characterizing the genomic response to low versus moderate doses of ionizing radiation (LDIR versus MDIR) in a three-dimensional (3D) skin model, which exhibits a closer tissue complexity to human skin than monolayer cell cultures. EpiDermFT skin plugs were exposed to 0, 0.1 and 1 Gy doses of X-rays and harvested at 5 min, 3, 8 and 24 h post-irradiation (post-IR). RNA was interrogated for global gene expression alteration. Our results show that MDIR modulated a larger number of genes over the course of 24 h compared to LDIR. However, immediately and throughout the first 3h post-IR, LDIR modulated a larger number of genes than MDIR, mostly associated with cell-cell signaling and survival promotion. Significant modulation of pathways was detected only at 3 h post-IR in MDIR with induction of genes promoting apoptosis. Collectively, the data show different dynamics in the response to LDIR versus MDIR, especially in cell-cycle distribution. LDIR-exposed tissues showed signs of attempted cell-cycle re-entry as early as 3 h post-IR, but were arrested beyond 8 h at the G1/S checkpoint. At 24 h, cells appeared to accumulate at the G2/M checkpoint. MDIR-exposed tissues did not exhibit a prolonged G1/S arrest but rather a prolonged G2/M arrest, which was sustained at least up to 24 h. By 24 h cells exhibited signs of recovery in both LDIR- and MDIR-exposed tissues. In summary, the most pronounced difference in the initial cellular response to LDIR versus MDIR is the promotion of protection and survival in LDIR versus the promotion of apoptosis in MDIR.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22915785 PMCID: PMC3483859 DOI: 10.1093/jrr/rrs063
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.Venn diagram illustrating the numbers of significantly differentially expressed genes.
Functional pathways represented by significant differentially expressed genes
| Time post-irradiation | 5 min | 3 h | 8 h | 24 h | |||||
|---|---|---|---|---|---|---|---|---|---|
| Dose (Gy) | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | |
| ANLN | Anillin | –a | – | 0.028 ↓ | 0.015 ↓ | 0.003 ↓ | <0.001 ↓ | ||
| AURKA | Aurora A | – | – | – | – | – | – | 0.033 ↓ | 0.005 ↓ |
| AURKB | Aurora B | – | – | – | – | – | 0.007 ↓ | 0.028 ↓ | 0.003 ↓ |
| BARD1 | Bard1 | – | – | 0.021 ↓ | – | 0.011 ↓ | <0.001 ↓ | – | <0.001 ↓ |
| BCL2L11 | Bim | – | – | – | 0.020 ↑ | – | – | – | |
| BID | Bid | 0.010 ↑ | – | 0.002 ↑ | 0.004 ↑ | – | – | 0.044 ↑ | |
| BIRC3 | c-IAP2 | 0.009 ↑ | – | 0.007 ↑ | – | – | – | – | 0.050 ↑ |
| BIRC5 | Survivin | – | – | 0.034 ↓ | – | – | 0.012 ↓ | – | 0.045 ↓ |
| BRCA1 | Brca1 | – | – | – | – | 0.006 ↓ | <0.001 ↓ | – | – |
| CASP1 | Caspase-1 | 0.008 ↓ | – | – | – | – | – | 0.008 ↓ | 0.003 ↓ |
| CASP6 | Caspase-6 | – | 0.043 ↑ | 0.038 ↓ | – | – | – | 0.002 ↓ | 0.004 ↓ |
| CASP9 | Caspase-9 | – | – | – | 0.028 ↑ | 0.048 ↑ | <0.001 ↑ | <0.001 ↑ | |
| CCNA2 | Cyclin A | – | – | – | – | – | 0.013 ↓ | 0.048 ↓ | 0.013 ↓ |
| CCNB1 | Cyclin B1 | – | – | 0.025 ↓ | – | – | 0.037 ↓ | 0.010 ↓ | 0.006 ↓ |
| CCNB2 | Cyclin B2 | – | – | – | – | – | 0.022 ↓ | 0.014 ↓ | 0.004 ↓ |
| CDC2 | CDK1 (p34) | – | – | 0.024 ↓ | – | 0.008 ↓ | 0.004 ↓ | 0.004 ↓ | |
| CDC7 | CDC7 | – | – | – | 0.008 ↓ | – | 0.005 ↓ | – | |
| CDC20 | CDC20 | – | – | – | – | – | 0.027 ↓ | – | – |
| CDC25A | CDC25A | – | – | – | 0.036 ↓ | 0.016 ↓ | <0.001 ↓ | – | – |
| CDC25B | CDC25B | – | – | – | – | 0.003 ↓ | 0.029 ↓ | ||
| CDC25C | CDC25C | – | – | – | – | – | – | 0.001 ↓ | <0.001 ↓ |
| CDK2 | CDK2 | – | – | 0.017 ↑ | – | – | 0.008 ↑ | – | |
| CDK6 | CDK6 | <0.001 ↑ | – | 0.047 ↑ | – | – | – | – | 0.008 ↑ |
| CDKN1A | p21 | – | 0.015 ↑ | <0.001 ↑ | 0.025 ↑ | <0.001 ↑ | – | 0.008 ↑ | |
| CDT1 | Cdt1 | – | – | – | – | – | 0.006 ↓ | – | – |
| CKS1B | CKS1 | – | – | 0.029 ↓ | – | – | 0.006 ↓ | – | – |
| DRAM | DRAM | 0.002 ↑ | – | 0.033 ↑ | – | <0.001 ↑ | – | 0.016 ↑ | |
| FANCD2 | FANCD2 | – | – | – | – | – | 0.012 ↓ | – | – |
| FAS | FasR (CD95) | – | – | – | 0.009 ↑ | – | – | – | |
| FBXW7 | F-box W7 | – | – | 0.012 ↓ | – | 0.003 ↓ | 0.020 ↓ | ||
| FOS | c-Fos | 0.004 ↓ | – | <0.001 ↑ | – | 0.048 ↑ | 0.038 ↓ | 0.024 ↓ | |
| GADD45A | GADD45α | – | – | 0.006 ↑ | – | – | – | ||
| HSPA2 | HSP70 prtn2 | 0.006 ↓ | – | 0.002 ↓ | – | – | – | <0.001 ↓ | <0.001 ↓ |
| IL6 | IL-6 | 0.011 ↑ | – | 0.010 ↑ | 0.011 ↑ | – | 0.023 ↑ | – | |
| IRAK2 | IRAK2 | 0.021 ↑ | – | 0.036 ↑ | – | – | – | 0.023 ↑ | 0.002 ↑ |
| IRAK3 | IRAK3 | 0.006 ↑ | – | 0.036 ↑ | – | – | 0.040 ↑ | 0.023 ↑ | |
| JUN | c-Jun | <0.001 ↑ | – | 0.015 ↑ | 0.004 ↑ | – | 0.022 ↑ | – | |
| KIF11 | KNSL1 | – | – | – | 0.048 ↓ | – | 0.022 ↓ | 0.003 ↓ | 0.002 ↓ |
| LIG3 | DNA ligase III | – | 0.016 ↓ | – | – | – | – | 0.011 ↑ | 0.037 ↑ |
| LMNB1 | Lamin B1 | – | – | – | – | – | 0.009 ↓ | – | – |
| MAP3K4 | MEKK4 | – | – | – | – | 0.026 ↑ | – | 0.021 ↑ | |
| MAPK10 | JNK | – | 0.021 ↑ | 0.030 ↑ | 0.037 ↑ | – | 0.030 ↑ | 0.015 ↑ | |
| MCM (2-7) | MCM complex | – | – | – | – | – | <0.001 ↓ | – | – |
| MCM10 | MCM complex | – | – | – | 0.037 ↓ | 0.017 ↓ | <0.001 ↓ | – | 0.032 ↓ |
| MDM2 | MDM2 | – | – | – | 0.029 ↑ | – | 0.003 ↑ | – | – |
| MDM4 | MDM4 | – | 0.007 ↑ | – | – | – | 0.043 ↑ | – | – |
| MMP1 | MMP-1 | 0.014 ↑ | – | – | – | – | – | – | |
| MMP2 | MMP-2 | 0.038 ↑ | – | 0.004 ↑ | – | – | 0.017 ↑ | – | 0.033 ↑ |
| MYL9 | MYRL2 | 0.015 ↓ | – | 0.002 ↓ | 0.002 ↓ | 0.004 ↓ | 0.010 ↓ | 0.017 ↓ | |
| NADE | BEX3 | 0.019 ↓ | 0.048 ↓ | 0.017 ↓ | 0.027 ↓ | 0.021 ↓ | – | ||
| NCAPG | CAP-G | – | – | – | 0.003 ↓ | 0.035 ↓ | 0.003 ↓ | ||
| NFKB2 | NF-κB (p52) | 0.022 ↑ | – | 0.033 ↑ | 0.016 ↑ | – | – | – | – |
| NMT1 | N-myristoyl-transferase | – | – | 0.038 ↑ | – | – | – | 0.029 ↑ | |
| NUMA1 | NUMA-1 | – | – | – | – | – | 0.017 ↓ | – | – |
| ORC1L | ORC1L | – | – | – | 0.042 ↓ | – | <0.001 ↓ | – | 0.033 ↓ |
| PARP1 | PARP-1 | – | – | – | 0.042 ↓ | 0.005 ↓ | 0.004 ↓ | 0.008 ↓ | |
| PARP2 | PARP-2 | – | 0.003 ↓ | 0.001 ↓ | <0.001 ↓ | 0.011 ↓ | |||
| PCNA | PCNA | – | – | 0.012 ↓ | – | 0.037 ↓ | – | 0.039 ↓ | |
| PLK1 | PLK1 | – | – | – | 0.004 ↓ | – | – | – | <0.001 ↓ |
| PLK4 | PLK4 | – | – | – | – | – | 0.006 ↓ | – | 0.035 ↓ |
| PMAIP1 | NOXA | – | – | – | 0.001 ↑ | – | – | – | – |
| POLD1 | POL delta cat (p125) | – | 0.002 ↓ | 0.024 ↓ | – | – | 0.002 ↓ | – | – |
| POLE2 | POL epsilon 2(p59) | – | – | – | 0.049 ↓ | – | 0.003 ↓ | – | – |
| PTGS2 | COX-2 | 0.029 ↑ | – | 0.002 ↑ | 0.003 ↑ | – | 0.034 ↑ | – | |
| PTTG1 | Securin | – | – | – | – | – | – | 0.022 ↓ | 0.032 ↓ |
| RAD1 | RAD1 | 0.019 ↓ | – | 0.007 ↓ | 0.002 ↓ | – | – | – | – |
| RAD23B | RAD23B | – | – | 0.027 ↓ | – | – | 0.017 ↓ | <0.001 ↓ | |
| RAD51AP1 | RAD51AP1 | – | – | 0.023 ↓ | <0.001 ↓ | 0.002 ↓ | |||
| RAD51C | RAD51C | – | – | 0.003 ↓ | 0.027 ↓ | 0.024 ↓ | 0.012 ↓ | – | – |
| RB1 | Rb protein | – | 0.023 ↑ | 0.006 ↑ | – | 0.012 ↑ | – | ||
| RBBP7 | Histone deacet-lase class I | – | – | – | 0.019 ↓ | – | – | – | 0.023 ↓ |
| RBL2 | p130 | – | – | 0.014 ↑ | 0.018 ↑ | – | – | – | |
| RELB | RelB (NF-κB) | 0.016 ↑ | – | 0.032 ↑ | – | – | 0.048 ↑ | 0.036 ↑ | 0.003 ↑ |
| RFC3/4/5 | RFC complex | – | – | 0.032 ↓ | 0.016 ↓ | – | 0.002 ↓ | – | |
| SKP2 | SKP2 | – | – | 0.031 ↓ | 0.019 ↓ | 0.033 ↓ | – | 0.002 ↓ | |
| SMC4 | CAP-C | – | – | – | – | – | 0.006 ↓ | <0.001 ↓ | |
| SOD2 | SOD2 | 0.018 ↑ | 0.009 ↑ | 0.042 ↑ | – | 0.025 ↑ | 0.017 ↑ | ||
| STAT3 | STAT-3 | – | – | 0.010 ↑ | 0.004 ↑ | – | 0.033 ↑ | 0.047 ↓ | – |
| STAT5B | STAT-5B | – | – | – | – | 0.002 ↑ | – | – | |
| SUMO1 | SUMO-1 | – | – | – | 0.005 ↓ | – | – | – | 0.007 ↓ |
| TNFRSF1A | TNF-R1 | 0.021 ↓ | 0.011 ↓ | – | – | – | – | – | – |
| TNFRSF1B | TNF-R2 | <0.001 ↑ | 0.006 ↑ | – | – | – | – | 0.002 ↑ | 0.009 ↑ |
| TNFRSF10B | DR5 | – | – | 0.005 ↑ | – | 0.031 ↑ | – | 0.006 ↑ | |
| TP53BP2 | TP53BP2 | <0.001 ↑ | – | – | 0.042 ↑ | – | 0.003 ↑ | – | 0.006 ↑ |
| TP53I3 | TP53I3 | 0.038 ↓ | – | 0.029 ↓ | 0.003 ↓ | – | 0.083 ↓ | – | – |
| TP53INP1 | TP53INP1 | 0.017 ↓ | – | 0.013 ↓ | 0.038 ↑ | – | 0.023 ↑ | – | – |
Genes were considered significant at P < 0.05. Genes with P-values in font were not included in the pathway analysis for that specific dose-time combination but are included in the tables to demonstrate their pattern of expression if exhibiting modulation at P < 0.1. ano significant modulation, b↑ is upregulation and ↓ is downregulation.
Total number of significantly modulated pathways
| Time post-IR | 5 min | 3 h | 8 h | 24 h | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose (Gy) | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | ||||
| total number | common | total number | common | total number | common | total number | common | |||||
| 0 | 0 | – | 1 | 0 | 0 | 5 | 4 | 4 | 1 | 1 | 1 | |
| 0 | 0 | – | 8 | 2 | 2 | 6 | 13 | 5 | 10 | 10 | 8 | |
| 11 | 0 | – | 7 | 9 | 2 | 3 | 5 | 2 | 0 | 9 | 0 | |
| 15 | 0 | – | 4 | 7 | 3 | 0 | 6 | 0 | 1 | 4 | 1 | |
| 8 | 0 | – | 7 | 10 | 4 | 0 | 7 | 0 | 4 | 20 | 4 | |
| 2 | 0 | – | 3 | 3 | 2 | 0 | 4 | 0 | 0 | 2 | 0 | |
| 0 | 0 | – | 1 | 1 | 1 | 2 | 0 | 0 | 3 | 2 | 2 | |
| 12 | 0 | – | 4 | 6 | 0 | 5 | 6 | 0 | 5 | 8 | 3 | |
Significantly differentially expressed genes in EpiDermFT exposed to 10 or 1 Gy over a course of 24 h post-IR were placed in functional pathways using MetaCore pathway analysis.
Differentially expressed genes that were placed in pathways.
| Time post-irradiation | 5 min | 3 h | 8 h | 24 h | ||||
|---|---|---|---|---|---|---|---|---|
| Dose (Gy) | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 |
| ATM/ATR regulation of G1/S checkpoint | – | – | 2.96 | NS* | 8.61 | 6.55 | – | – |
| Brca1 as a transcription regulator | – | – | NS | NS | 2.87 | 2.98 | – | – |
| ATM/ATR regulation of G2/M checkpoint | – | – | – | – | 4.25 | 6.38 | 4.38 | 3.87 |
| Role of Brca1 and Brca2 in DNA repair | – | – | – | – | 4.19 | 2.98 | – | – |
| – | – | 5.09 | 3.16 | 7.28 | 3.94 | NS | 3.59 | |
| – | – | 5.61 | 5.55 | 5.42 | 5.40 | NS | 3.27 | |
| – | – | – | – | NS | 7.65 | – | – | |
| – | – | 3.28 | NS | 5.79 | 6.07 | 5.28 | 2.77 | |
| – | – | – | – | NS | 3.76 | 3.69 | NS | |
| – | – | 3.81 | NS | 2.79 | 8.80 | 9.67 | 12.64 | |
| – | – | – | – | NS | 3.88 | 9.01 | 6.86 | |
| – | – | – | – | 2.75 | 7.49 | 9.50 | 6.23 | |
| – | – | – | – | NS | 5.06 | 9.04 | 13.13 | |
| – | – | – | – | NS | 4.39 | 5.64 | 6.18 | |
| Role of Nek in cell cycle regulation | – | – | – | – | – | – | 7.13 | 4.28 |
| Anti-apoptotic TNFs/NF-κB/Bcl-2 pathway | 4.55 | NS | 3.91 | NS | – | – | – | – |
| Anti-apoptotic TNFs/NF-κB/IAP pathway | 3.87 | NS | 3.37 | NS | – | – | – | – |
| Apoptosis plus 090609 | – | – | NS | 3.96 | 2.87 | 6.85 | NS | 3.51 |
| Apoptotic TNF-family pathways | 2.79 | NS | NS | 3.01 | – | – | NS | 2.70 |
| FAS signaling cascades | 3.53 | NS | NS | 3.71 | NS | 2.83 | NS | 3.43 |
| Granzyme B signaling | 2.57 | NS | 2.96 | 4.69 | NS | 3.65 | NS | 2.50 |
| p53-dependent apoptosis | – | – | NS | 3.16 | 2.91 | 5.92 | NS | 2.69 |
| Role of IAP-proteins in apoptosis | 3.52 | NS | 5.86 | NS | NS | 2.90 | NS | 5.39 |
| TNFR1 signaling pathway | 5.32 | NS | 4.59 | 2.94 | – | – | NS | 2.65 |
| Gastrin in inflammatory response | – | – | 2.96 | 3.56 | – | – | NS | 3.50 |
| IL-1 signaling pathway | 2.68 | NS | 2.92 | 3.64 | NS | 2.77 | – | – |
| IL-2 activation and signaling pathway | 3.97 | NS | NS | 3.30 | NS | 2.50 | 2.81 | 3.07 |
| IL-3 activation and signaling pathway | 2.64 | NS | – | – | NS | 2.90 | – | – |
| IL-6 signaling pathway | 3.69 | NS | 3.20 | 4.06 | NS | NS | – | – |
| IL-7 signaling in T lymphocytes | – | – | NS | 2.52 | NS | 3.17 | – | – |
| IL-22 signaling pathway | 2.51 | NS | NS | 2.85 | NS | 2.75 | – | – |
| MIF-mediated glucocorticoid regulation | 5.57 | NS | NS | 2.90 | – | – | – | – |
| TLR signaling pathways | 2.82 | NS | 2.95 | NS | – | – | – | – |
| A2B receptor: action via G-protein alpha s | 2.39 | NS | – | – | – | – | NS | 2.31 |
| EGFR signaling via small GTPases | – | – | – | – | – | – | NS | 2.50 |
| Endothelin-1/EDNRA signaling | – | – | – | – | – | – | NS | 3.61 |
| Gastrin in cell growth and proliferation | 2.56 | NS | NS | 3.95 | – | – | NS | 2.47 |
| GDNF family signaling | – | – | NS | 3.50 | – | – | NS | 2.49 |
| Glucocorticoid receptor signaling | 4.18 | NS | NS | 3.64 | – | – | 3.50 | 3.08 |
| Growth hormone signaling via STATs and PLC/IP3 | – | – | – | – | NS | 2.61 | – | – |
| HGF signaling pathway | – | – | NS | 3.43 | – | – | NS | 2.45 |
| HGF-dependent inhibition of TGF-beta-induced EMT | 4.39 | NS | 2.96 | 2.92 | NS | 4.55 | 2.90 | 4.28 |
| IGF-1 receptor signaling | – | – | NS | 2.50 | – | – | NS | 2.96 |
| Regulation of epithelial-to-mesenchymal (EMT) transition | 3.15 | NS | 4.63 | NS | NS | 2.41 | – | – |
| SSTR1 in regulation of cell proliferation and migration | – | – | – | – | – | – | NS | 2.69 |
| TGF-beta receptor signaling | – | – | NS | 3.24 | – | – | NS | 2.31 |
| TGF-beta-dependent induction of EMT via MAPK | 2.53 | NS | – | – | NS | 2.60 | – | – |
| Thrombopoietin-regulated cell processes | – | – | 2.86 | 3.57 | NS | 4.22 | NS | 4.13 |
| WNT signaling pathway. Part 1. Degradation of beta-catenin in the absence WNT signaling | – | – | – | – | – | – | 2.82 | 2.48 |
| WNT signaling pathway. Part 2 | – | – | 5.46 | 5.39 | NS | 2.94 | 5.14 | 4.41 |
| NF-κB signaling pathway | 3.88 | NS | 2.56 | NS | – | – | – | – |
| Role of AP-1 in regulation of cellular metabolism | 3.02 | NS | 2.56 | 5.00 | NS | 3.97 | – | – |
| P53 signaling pathway | – | – | 4.07 | 4.90 | NS | 4.75 | NS | 2.87 |
| Role of Akt in hypoxia induced HIF1 activation | – | – | NS | 3.34 | NS | 3.24 | – | – |
| Chemokines and adhesion | 2.46 | NS | 2.87 | NS | – | – | 2.96 | 2.89 |
| ECM remodeling | 2.31 | NS | – | – | – | – | NS | NS |
| cadherin-mediated cell adhesion | – | – | NS | 2.56 | – | – | – | – |
| Integrin-mediated cell adhesion and migration | – | – | – | – | – | – | NS | 3.40 |
| Cytoskeleton remodeling | – | – | NS | NS | 3.05 | NS | 3.54 | 4.04 |
| TGF, WNT and cytoskeletal remodeling | NS | NS | 4.77 | 5.34 | 3.80 | NS | 5.28 | 6.40 |
| CFTR folding and maturation (norm and CF) | – | – | 3.95 | NS | 2.34 | NS | – | – |
| Mucin expression in CF via IL-6, IL-17 signaling pathways | 3.29 | NS | NS | 3.59 | NS | 2.68 | – | – |
| Mucin expression in CF via TLRs, EGFR signaling pathways | 2.35 | NS | NS | 2.50 | – | – | – | – |
| Muscle contraction: Regulation of eNOS activity in endothelial cells | 3.15 | NS | 2.57 | NS | – | – | NS | 2.39 |
| Parkin disorder under Parkinson's disease | 3.69 | NS | NS | 2.54 | NS | 2.46 | – | – |
| Proteolysis: Putative SUMO-1 pathway | – | – | NS | 3.16 | – | – | – | – |
| Proteolysis: Role of Parkin in the Ubiquitin-Proteasomal pathway | 3.16 | NS | NS | 2.72 | NS | 2.64 | NS | NS |
| Pyruvate metabolism | 2.44 | NS | 2.64 | NS | NS | 3.92 | – | – |
| Reproduction: GnRH signaling | 2.81 | NS | NS | 3.40 | NS | 2.65 | NS | 2.70 |
Selected pathways significantly modulated in EpiDermFT exposed to 0.1 or 1 Gy. Pathways were considered as significant at false discovery rate (FDR) < 5%. The significant values are presented in the table as the negative log transformation of the P-value. *The modulation of the pathway was calculated as not significant (FDR < 0.05). NS means not significant, – means that the expression of the gene considered was not significantly changed at the given dose and time.
Fig. 2.Illustration of the metaphase checkpoint pathway.
Fig. 3.Representation of the significance level of cellular processes.